Phase I trial to evalaute the effects of a single dose of MEM 63908 in elderly volunteers
Phase of Trial: Phase I
Latest Information Update: 18 Jan 2010
At a glance
- Drugs Facinicline (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Memory Pharmaceuticals
- 26 Sep 2008 Top-line results are expected from the full phase I program in quarter 4 2008, as reported in a Memory Pharmaceuticals media release.
- 26 Sep 2008 Status changed from recruiting to completed as reported in a Memory Pharmaceuticals media release.
- 06 Mar 2008 Status changed from planning to recruiting, according to a Memory Pharmaceuticals media release.